The Technical Analyst
Enlivex Therapeutics Ltd [ENLV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Enlivex Therapeutics Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.71% $1.320
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 24.54 mill |
| EPS: | -1.470 |
| P/E: | -0.900 |
| Earnings Date: | Apr 22, 2024 |
| SharesOutstanding: | 18.59 mill |
| Avg Daily Volume: | 0.171 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.900 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.900 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0057 (-100.43%) $-1.326 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.984 - 1.676 ( +/- 26.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2015-10-09 | Murray Michael Anthony | Sell | 56 390 | Common Stock |
| 2008-01-02 | Weatherson Harvey D | Buy | 12 000 | Option to purchase Common Stock |
| 2008-01-02 | Raney Dennis R | Buy | 12 000 | Option to purchase Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 3 transactions |
| Buy: 24 000 | Sell: 56 390 |
Forecast:
16:00 - $1.330
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.330
Forecast 2: 16:00 - $1.330
Forecast 3: 16:00 - $1.330
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.320 (-5.71% ) |
| Volume | 0.108 mill |
| Avg. Vol. | 0.171 mill |
| % of Avg. Vol | 62.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENLV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ENLV
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Latest Press Releases
2024-04-16 07:50:00 - Press Release
Enlivex Announces Authorization From The Danish Regulatory Agency For The Company's Randomized, Controlled Phase I/ii Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Nes-ziona, israel, april 16, 2024 (globe newswire) -- enlivex therapeutics ltd. (nasdaq: enlv, the “company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the danish medicines agency (dkma) authorized the expansion into denmark of the company's multi-country, randomized, controlled phase i/ii trial evaluating allocetratm in up to 160 patients with moderate to severe knee osteoarthritis. as previously announced, the company received its first regulatory approval for this trial from the israeli ministry of health (imoh) in january.
2024-04-11 14:58:00 - Press Release
Enlivex To Host Webcast On April 12, 2024 At 8:30 A.m. Eastern Time To Discuss Topline Results From Its Phase Ii Trial Evaluating Allocetra™ In Patients With Sepsis
Nes-ziona, israel, april 11, 2024 (globe newswire) -- enlivex therapeutics ltd. (nasdaq: enlv, the “company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will host a conference call and webcast on april 12, 2024, at 8:30am et (15:30 il time) to discuss topline results from its phase ii trial of allocetra™ in patients with sepsis, in which 120 patients enrolled. during the call, members of enlivex's leadership team will discuss the results. a live q&a session will follow the company's prepared remarks.
2024-04-11 08:05:00 - Press Release
Enlivex Announces Topline Results Of Its Phase Ii Trial Evaluating Allocetra™ In Patients With Sepsis
Nes-ziona, israel, april 11, 2024 (globe newswire) -- enlivex therapeutics ltd. (nasdaq: enlv, the “company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive indication of effect and safety results from its phase ii study of allocetra™ in patients with sepsis, in which 120 patients enrolled.
2024-03-22 10:50:00 - Press Release
Enlivex Therapeutics And Unusual Machines Interviews To Air On The Redchip Small Stocks, Big Money(tm) Show On Bloomberg Tv
Orlando, fl / accesswire / march 22, 2024 / redchip companies will air interviews with enlivex therapeutics ltd. (nasdaq:enlv) and unusual machines inc. (nyse american:umac) on the redchip small stocks, big money™ show, a sponsored program on bloomberg tv, this saturday, march 23, at 7 p.m.
2024-02-26 08:30:00 - Press Release
Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Nes-ziona, israel / accesswire / february 26, 2024 / as we age, our knees start aching for reasons we can't quite pinpoint. medicines temporarily decrease pain but don't help with the inflammatory chronic condition and the chronic pain comes back again, while physical therapy rarely works as well as we hope it will.
Latest News
2024-04-15 14:05:13 - Zacks Investment Research
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
2024-04-11 14:58:00 - GlobeNewsWire
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will host a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss topline results from its Phase II trial of Allocetra™ in patients with sepsis, in which 120 patients enrolled. During the call, members of Enlivex's leadership team will discuss the results. A live Q&A session will follow the Company's prepared remarks.
2023-11-03 09:02:20 - Zacks Investment Research
New Strong Buy Stocks for November 3rd
XRX, GVA, CUBI, LXU and ENLV have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2023.
2023-10-27 07:31:44 - Zacks Investment Research
New Strong Buy Stocks for October 27th
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
2023-10-19 08:16:22 - Zacks Investment Research
New Strong Buy Stocks for October 19th
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
2023-06-06 08:00:00 - GlobeNewsWire
Enlivex to Present at the 2023 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff281/enlv/1860430, and will be archived for 90 days.
2022-10-03 08:13:00 - GlobeNewsWire
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.
2022-09-30 02:08:20 - Seeking Alpha
Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders.
2022-06-07 08:00:00 - GlobeNewsWire
Enlivex to Present at the 2022 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 1:00 PM Eastern Time. A webcast of the presentation will be available at https://wsw.com/webcast/jeff240/enlv/1853925 , and will be archived for 90 days.
2021-12-06 10:48:02 - Pulse2
Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today
The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.